This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Long-term treatment: LUX-Lung 3, 6, 7 and 8
In the LUX-Lung 3, LUX-Lung 6 and LUX-Lung 7 studies, 10–12% of afatinib-treated* patients were long-term responders (LTRs; treated for ≥3 years).1 In LUX-Lung 7, 12% of afatinib-treated patients versus 4% of gefitinib patients were LTRs. Long-term treatment was independent of tolerability-guided dose adjustment and of the presence of brain metastases at time of enrolment. Long-term treatment with afatinib had no detrimental impact on subsequent treatment.1
Patients treated for at least 2, 2.5 and 3 years in the overall LUX-Lung 3, 6 and 7 populations1,2
Note: For LUX-Lung 7, percentages are based on total number of patients who received treatment with afatinib or gefitinib
In LUX-Lung 8, 21 out of 398 patients in the afatinib arm were long-term responders who had received at least 12 months of afatinib treatment.3 Median treatment duration in these patients was 17.6 months (range 12.3–27.6 months). Median progression-free survival (PFS) was 16.6 months (range 2.8–25.8) and median overall survival (OS) was 21.1 months (range 12.9–31.6); one patient had a complete response and six patients had a partial response.3
Schuler M, et al. Eur J Cancer 2017;72(Suppl. 1):S176-S7.
Yang JC-H, et al. Presented at the 2017 Japanese Society of Medical Oncology Annual Meeting (Abstract 70046).
Gadgeel SM, et al. Eur J Cancer 2017;72(Suppl. 1):S185.
*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: October 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue